Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 402
Montréal, Québec CA H4M 2X6




October 1, 2021


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn: Christopher Edwards


Re: Milestone Pharmaceuticals Inc.

Registration Statement on Form S-3

Filed June 25, 2021


File No. 333-257404 

  Acceleration Request
  Requested Date: Tuesday, October 5, 2021
  Requested Time: 4:00 P.M. Eastern Time


Ladies and Gentlemen:


In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-257404) (the “Registration Statement”) to become effective on Tuesday, October 5, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.


The Registrant hereby authorizes each of Marc Recht, Ryan Sansom and Layne Jacobs of Cooley LLP to make such request on its behalf.


Once the Registration Statement has been declared effective, please orally confirm that event with Layne Jacobs of Cooley LLP, counsel to the undersigned registrant, at (617) 937-2321.


[Signature Page Follows]





Milestone Pharmaceuticals Inc.

/s/ Joseph Oliveto


  Joseph Oliveto  
  Chief Executive Officer  


cc: Amit Hasija, Milestone Pharmaceuticals Inc.
Ryan Sansom, Cooley LLP
Layne Jacobs, Cooley LLP